Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Lynette Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, Sumita Ratnasingam, Sonia Raj, Pohan Lukito, David Yeung, Timothy Hughes, Naranie Shanmuganathan

Research output: Contribution to journalArticlepeer-review

Abstract

Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.

Original languageEnglish
JournalInternal Medicine Journal
DOIs
Publication statusAccepted/In press - 2024

Keywords

  • asciminib
  • chronic myeloid leukaemia
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Internal Medicine

Cite this